Ndonovo Therapeutics Inc (ENDV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2023 | 12-2022 | 12-2021 | 12-2020 | 12-2019 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 2 | 0 | 86 | 13 | 19 |
| Receivables | N/A | N/A | 1 | 1 | 23 |
| TOTAL | $20 | $16 | $95 | $46 | $63 |
| Non-Current Assets | |||||
| PPE Net | N/A | N/A | N/A | 2 | 6 |
| Intangibles | 619 | 1,265 | 1,912 | 2,559 | 3,206 |
| TOTAL | $619 | $1,265 | $1,912 | $2,561 | $3,212 |
| Total Assets | $638 | $1,281 | $2,007 | $2,607 | $3,275 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 1,083 | 884 | 659 | 701 | 600 |
| Accrued Expenses | 4,757 | 3,543 | 2,529 | 1,904 | 1,317 |
| Other current liabilities | 11,754 | 21,802 | 7,334 | 7,587 | 14,845 |
| TOTAL | $24,666 | $33,382 | $17,702 | $16,826 | $23,624 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 80 | 80 | 80 | 155 | 155 |
| TOTAL | $80 | $80 | $80 | $155 | $155 |
| Total Liabilities | $24,746 | $33,462 | $17,782 | $16,981 | $23,779 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 318,752 | 270,285 | 149,528 | 53,576 | 8,814 |
| Common Shares | 33 | 21 | 7 | 3 | 0 |
| Retained earnings | -68,234 | -75,119 | -56,443 | -53,339 | -52,935 |
| Other shareholders' equity | -2 | -2 | -2 | -2 | -2 |
| TOTAL | $-24,108 | $-32,180 | $-15,774 | $-14,374 | $-20,504 |
| Total Liabilities And Equity | $638 | $1,281 | $2,007 | $2,607 | $3,275 |